Combined Phase I/II Clinical Study of EMD531444(L-BLP25 or BLP25 Liposome Vaccine) in Subjects With Stage III Unresectable Non-small Cell Lung Cancer Following Primary Chemoradiotherapy.

Trial Profile

Combined Phase I/II Clinical Study of EMD531444(L-BLP25 or BLP25 Liposome Vaccine) in Subjects With Stage III Unresectable Non-small Cell Lung Cancer Following Primary Chemoradiotherapy.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Tecemotide (Primary) ; Cyclophosphamide
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Merck KGaA
  • Most Recent Events

    • 23 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 15 May 2015 According to a Merck and Co. media release, data from this study will be presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top